The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.
Showing results 1 - 10 of 41
Coordinating Implementation Science for CAB for PrEP: Early Insights from EBONI and PILLAR
This document summarises key takeaways from the BioPIC Think Tank on early insights from ViiV Healthcare’s two cabotegravir for PrEP implementation studies- EBONI and PILLAR.
Research, Service Delivery
Efficacy and Safety of Long-Acting Cabotegravir Compared with Daily Oral Tenofovir Disoproxil Fumarate Plus Emtricitabine to Prevent HIV Infection in Cisgender Men and Transgender Women who Have Sex with Men 1 Year after Study Unblinding: A secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
This article from The Lancet HIV describes findings from the first unblinded year of the HIV Prevention Trials Network (HPTN) 083 study, which compared safety and efficacy of cabotegravir and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as HIV prevention for transgender women and men who have sex with men in Argentina, Brazil, Peru, South Africa, Thailand, the…
PrEP Ring Research Summary
This document is an overview of PrEP ring research in East and Southern Africa, including trial overviews and key findings.
Ring 101 Slide Deck
These slides give an overview of the dapivirine ring, including basic information about how it's used, clinical trial results, user experience, and upcoming studies and products.
Coordinating Implementation Science for CAB for PrEP: Inclusion of Key Populations
This document summarises key takeaways from the BioPIC Think Tank focused on strategies to include trans and gender diverse people, gay and bisexual men who have sex with men, sex workers, and people who use and inject drugs in implementation science projects as well as the rollout and scale-up of cabotegravir for PrEP.
Efficacy, Safety, Tolerability, and Pharmacokinetics of Long-acting Injectable Cabotegravir for HIV Pre-exposure Prophylaxis in Transgender Women: A secondary analysis of the HPTN 083 trial
This article from the Lancet HIV discusses the results of a secondary analysis of data from the HPTN 083 trial of cabotegravir for PrEP, looking specifically at the cohort of transgender women included in the study.
Injectable PrEP Factsheet for Transgender and Gender-Nonbinary Advocates and Community Members in the Asia-Pacific Region
This factsheet raises awareness of injectable cabotegravir (CAB) for PrEP and describes actions community members can take to advocate for the approval and availability of CAB for PrEP in their country in the Asia Pacific region. This factsheet is designed for transgender and non-binary advocates and community members- another for gay, bisexual, and other men…
Resources for Conducting Gender-Inclusive Research
These resources, compiled by HIV/AIDS Network Coordination, can support researchers to conduct gender-inclusive HIV research. This includes guidance on data collection, gender-inclusive HIV research practices, a scorecard for gender diverse inclusion in research, and training materials.
Feasibility of Long Acting Injectable Cabotegravir PrEP Initiation and Administration by Community Health Workers and Early Aspects of the PrEP Injection Care Continuum in a Primary Care Center in Washington, D.C.
This poster presentation, delivered at IAS 2023 by the Whitman-Walker Institute, describes the integration of long acting injectable cabotegravir for PrEP, administered by community health workers, or non medically licensed staff, in a primary health clinic in Washington, D.C., USA.
Research, Service Delivery
A Scoping Review of Oral Pre-exposure Prophylaxis for Cisgender and Transgender Adolescent Girls and Young Women: What Works and Where Do We Go from Here?
This journal article from AIDS and Behavior explored results from interventions along the PrEP continuum for adolescent girls and young women (AGYW) to inform research and programs.